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Classification of cystic fibrosis and related disorders1
1. Background
Making a diagnosis of cystic fibrosis (CF) is not
always simple w1x. Initially, CF was recognised as a clin-
ical syndrome. Many diagnostic problems were resolved
by the development of the sweat test in 1950 w2x. The
test remains clinically reliable for most cases w3x, but the
occasional occurrence of false–negative and false–pos-
itive results has always been recognised. With the clon-
ing of the gene for the CF transmembrane conductance
regulator (CFTR) w4,5x in 1989, clinicians hoped that
genetic testing for CF would be both sensitive and spe-
cific. However, the more than 900 mutations so far iden-
tified in the CFTR gene have made genetic testing for
CF difficult to develop, and making a definitive diag-
nosis in atypical cases has become sometimes more,
rather than less, difficult.
Although the rarity of most mutations has made it
possible to screen by using a panel of 70 mutations with
a sensitivity approaching 90% in the general population
of the United States w6x, the complexity of the problem
has been increased by recognition that some conditions
caused by mutations in the CFTR gene fall short of the
criteria necessary for a diagnosis of cystic fibrosis. For
example, male infertility due to congenital bilateral
absence of the vas deferens w7,8x with or without mild
sinopulmonary disease, is commonly associated with
CFTR mutations. Recently, it has been shown that uni-
lateral vas deferens atresia may also be related to CFTR
mutations w9x. Recurrent or chronic pancreatitis is anoth-
er condition where a diagnosis of CF is not appropriate,
but in which CFTR mutations are frequently identified.
These disorders are not CF, but are CFTR-related.
2. The role of genotype
Genotype–phenotype correlation has proved to be
inconsistent even for those specific mutations shown to
be associated with ‘classical’ cystic fibrosis. Among
patients homozygous for the common delta F508 muta-
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tion, and even within families, a variety of different clin-
ical phenotypes and degrees of severity can be observed
w10x. Occasional individuals carrying two ‘severe’ muta-
tions may have no clinical evidence of disease, at least
in early life and may remain asymptomatic into the fifth
decade (Warwick W, personal communication). Others,
with typical CF features, may have no identifiable muta-
tions even when their CFTR genes have been sequenced
(Tsui, unpublished). This suggests that in addition to
environmental factors, at least one gene at another locus
(and probably more) may significantly affect the clinical
picture w11x. It further indicates that genotype alone is
an insufficient basis for the classification of clinical syn-
dromes associated with cystic fibrosis or the CFTR gene.
3. The diagnosis of cystic fibrosis
Features suggesting or confirming the diagnosis of CF
have recently been summarised in the US Consensus
document 1998 (Table 1) w12x. This statement serves
well as a reference point for the majority of cases, but
it does not take into account the fact that approximately
5% of otherwise typical (if usually mild) CF individuals
have negative sweat tests, and the alternative tests based
on nasal, duodenal or rectal potential difference, which
help to resolve doubtful cases, are not widely available.
Another recent approach has been to regard individ-
uals with a CF genotype, but no discernable clinical dis-
ease (e.g. some infants detected by neonatal screening)
as ‘pre-CF’ using the analogy of premalignant conditions
w13x. However, while indicating the need for such per-
sons to be kept under clinical surveillance, it begs the
question of how to classify subclinical disease and is not
a concept which has yet found wide acceptance.
4. A proposed classification for ICD-11
All officially recognised medical diagnoses are cate-
gorised in the International Classification of Diseases
(ICD) published by WHO. In the current edition (ICD
10), cystic fibrosis is placed in the section devoted to
Endocrine, Nutritional and Metabolic Diseases, Chapter
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Table 1
Phenotypic features consistent with a diagnosis of CF w12x
1. Chronic sinopulmonary disease manifested by:
dPersistent colonisationyinfection with typical CF pathogens including
Staphylococcus aureus, non-typeable Haemophilius influenzae, mucoid and
non-mucoid Pseudomonas aeruginosa, and Burkholderia cepacia.
dChronic cough and sputum production.
dPersistent chest radiograph abnormalities (e.g. bronchiectasis, atelectasis,
infiltrates, hyperinflation).
dAirway obstruction manifested by wheezing and air trapping.
dNasal polyps; radiographic or computed tomographic abnormalities
of the paranasal sinuses.
dDigital clubbing.
2. Gastrointestinal and nutritional abnormalities including:
dIntestinal: meconium ileus, distal intestinal obstruction syndrome, rectal prolapse.
dPancreatic: pancreatic insufficiency, recurrent pancreatitis.
dHepatic: chronic hepatic disease manifested by clinical or
histologic evidence of focal biliary cirrhosis or multilobular cirrhosis.
dNutritional: failure to thrive (protein–calorie malnutrition), hypoproteinemia and edema,
complications secondary to fat-soluble vitamin deficiency.
3. Salt loss syndromes: acute salt depletion, chronic metabolic alkalosis.
4. Male urogenital abnormalities resulting in obstructive azoospermia (CBAVD).
4. The classification for cystic fibrosis is subdivided into
four parts:
● E84.0 CF with pulmonary manifestations.
● E84.1 CF with intestinal manifestations.
● E84.8 CF with other manifestations.
● E84.9 CF unspecified.
It would be of benefit to patients, families, health care
providers, health insurers, medico-legal interests and cli-
nicians if this classification could be revised to take
account of current knowledge and diagnostic problems,
and to separately designate those related conditions
which are not CF, and whose diagnosis has different
implications.
WHO, ICF(M)A, ECFTN and ECFS therefore con-
vened a joint working group in June 2000 to produce a
new classification suitable for inclusion in the next edi-
tion of ICD due to be published in 2002 (ICD 11).
One possibility was to classify all conditions associ-
ated with a CFTR mutation as CFTR-Related, but this
would exclude patients in whom no mutation can be
found, and include others in whom the mutation is not
of clinical significance and not responsible for the clin-
ical features. There are currently more than 900 muta-
tions and more than 300 known polymorphisms in the
CFTR gene, but even so using CFTR as the essential
defining criterion would not cover all cases and would
be open to misinterpretation.
As ICD is a tool for clinicians, it was agreed that the
diagnostic classification should be made on clinical rath-
er than laboratory grounds, while acknowledging the
importance of identifying CFTR mutations in those per-
sons with clinical conditions such as pancreatitis w14x
and atresia of the vas deferens w9x where some, but not
all cases are CFTR-related. Some of these patients may
on detailed clinical and laboratory investigation, show
minor and previously unsuspected features of cystic
fibrosis, but in others there is no evidence of multisystem
disease to justify a diagnosis of atypical CF. Other con-
ditions in which some cases appear to be aetiologically
related to CFTR mutations include allergic bronchopul-
monary aspergillosis w15x, disseminated bronchiectasis
w16x, and diffuse panbronchiolitis w17x. There should be
appropriate cross-referencing in ICD to the same disor-
ders located elsewhere. Where a known mutation is
judged to be aetiologically related to the disease in an
individual, the primary diagnostic code should be
assigned from the section which includes CF.
It was also agreed to include a diagnostic category for
those infants with neonatal hypertrypsinogenemia who
are shown to have a single CFTR mutation, the majority
of whom will be healthy carriers, but a few will have an
undetected second mutation. There is no consensus on
the management of these cases, but at present there is
no code for their recording to facilitate future research.
The working group agreed that the overall heading for
the section should be ‘Cystic Fibrosis and Related Dis-
orders’ such as:
● Classical CF pancreatic-insufficient (PI).
● Classical CF pancreatic-sufficient (PS).
● Atypical CF.
● CF otherwise specified.
● CF not otherwise specified.
● Isolated obstructive azoospermia*.
● Chronic pancreatitis*.
● Allergic bronchopulmonary aspergillosis (ABPA)*.
● Disseminated bronchiectasis*.
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● Diffuse panbronchiolitis*.
● Sclerosing cholangitis*.
● Neonatal hypertrypsinogenemia.
*At least one CFTR mutation identified. It is likely
that this classification will need further revision in the
future as our knowledge and understanding of these con-
ditions increase.
5. List of participants
● Accurso, Frank: Children’s Hospital, 19th Avenue
1056 E-Box B395, CO 802 18 Denver, USA. Tel.: q
1-303-8372.522, fax: q1-303-8372.924, e-mail:
accurso.frank@tchden.org
Cabeza, Stella: Latin American CF Association, Costa
Rica 2061, 11500 Montevideo, Uruguay. Tel.: q598-
2-6003.842, fax: q598-2-2086.849, e-mail:
smcabeza@medmet.or.uy
Cassiman, Jean-Jacques: European CF Thematic Net-
work, KULeuven-Campus Gasthuisberg, Center for
Human Genetics, Herestraat 49, 3000 Leuven, Bel-
gium. Tel.: q32-16-34.58.61, fax: q32-16-34.59.97,
e-mail: jean-jacques.cassiman@med.kuleuven.ac.be
Corey, Mary: Hospital for Sick Children, University
Ave 555. University Wing, ON M5G 1X8 Toronto,
Canada. Tel.: q1-416-8135.750, fax: q1-416-
8135.292, e-mail: mary.corey@sickkids.on.ca
Davidson, A, George F: International CF(M) Asso-
ciation, University of British Columbia, BC’s Chil-
dren’s Hospital, Oak Street 4480, BC V6H 3VH
Vancouver, Canada. Tel.: q1-604-8752.142, fax: q
1-604-8752.349.
Dequeker, Els: European CF Thematic Network,
KULeuven-Campus Gasthuisberg, Center for Human
Genetics, Herestraat 49, 3000 Leuven, Belgium. Tel.:
q32-16-34.58.81, fax: q32-16-34.59.97, e-mail:
els.dequeker@med.kuleuven.ac.be (Rapporteur).
Dodge, John: University of Wales Swansea, Child
Health, Singleton Hospital, SA2 8QA Swansea, UK.
Tel.: q44-1792-205.666, fax: q44-1792-285.244, e-
mail: j.a.dodge@btinternet.com (Chairman).
Doring, Gerd: European CF Society, Hygiene Insti-¨
tute, Department of General and Environmental
Hygiene, Wilhelmstrasse 31, D-72074 Tubingen, Ger-¨
many. Tel.: q49-7071-298.20.69, fax: q49-7071-
293.011, e-mail: gerd.doering@uni-tuebingen.de
Heidet, Liliane: International CF(M) Association,
Chemin de la Montagne 124, 1224 Chene Bougeries,
Switzerland. Tel.: q41-22-3489.452, e-mail:
liliane.heidet@bluewin.ch
Heijerman, Harry: Leyenburg Hospital, Leyweg 275,
2545 CH The Hague, The Netherlands. Tel.:q31-70-
3592.076, fax: q31-70-3592.150, e-mail:
hgmheij@knmg.nl
Kotsimbos, Tom: Alfred Hospital Dept Resp Medi-
cine, Commercial rd Prahran 31-71, Melbourne 3181,
Australia. Tel.: q61-3-92763844, fax: q61-3-
92763434, e-mail: tom.kotsimbos@med.morsh.edu.au
Mastella, Gianni: Azienda Ospedaliera di Verona,
Cystic Fibrosis Center, Piazzale Stefani 1, 37126
Verona, Italy. Tel.: q39-45-80.72.370, fax: q39-45-
80.72.042.
Morrison, Cathleen: Canadian CF Foundation, Yonge
Street 2221 Suite 601, M4S 2B4 Toronto, Ontario,
Canada. Tel.: q1-416-4859.149y225, fax: q1-416-
4850.960, e-mail: cmorrison@ccff.ca
Pignatti, Pier Franco: European CF Thematic Net-
work, University of Verona, Mother and Child —
Biology and Genetics, Strada Le Grazie 8, 37134
Verona, Italy. Tel.: q39-45-58.46.02, fax: q39-45-
80.98.180, e-mail: pignatti@medgen.univr.it
Strandvik, Birgitta: Sahlgrenska University Hospital,
Department of Pediatrics, 416 85 Goteborg, Sweden.¨
e-mail: birgitta.strandvik@pediat.gu.se
Tsui, Lap-Chee: International CF Consortium, The
Hospital for Sick Children, Department of Genetics,
University Avenue 555, ONT M5G 1X8 Toronto,
Canada. Tel.: q1-416-8136.015, fax: q1-416-
8134.931, e-mail: lctsui@sickkids.on.ca
5.1. List of corresponding members2
● Beall, Robert: US CF Foundation, 6931 Arlington
Road, 2nd floor, Bethesda MD 20814 USA. Tel.: q
1-301-9072541, fax: q1-301-9072540, e-mail:
rjb@cff.org
WHO Secretariat
Boulyjenkov, Victor: World Health Organisation,
Department of Management of NCDs, Human Genet-
ics Programme, 1211 Geneva, Switzerland. Tel.: q
41-22-7913.442, fax: q41-22-7914.769, e-mail:
boulyjenkovv@who.ch
Acknowledgments
Printed with permission of the WHO.
References
w1x Wilmott RW. Making the diagnosis of cystic fibrosis. J Pedi-
atrics 1998;132:563–4.
Unable to be present, corresponding members.2
8 Meeting report
w2x Gibson LE, Cooke RE. A test for concentration of electrolytes
in sweat in cystic fibrosis of the pancreas utilizing pilocarpine
by iontopheresis. Pediatrics 1959;23:545–9.
w3x Legrys VA. Sweat testing for the diagnosis of cystic fibrosis:
pancreatic considerations. J Pediatr 1996;129:892–7.
w4x Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of
the cystic fibrosis gene; chromosome walking and jumping.
Science 1989;245:1059–65.
w5x Riordan JR, Rommens JM, Kerem B, et al. Identification of
the cystic fibrosis gene: cloning and characterisation of com-
plementary DNA. Science 1989;245:1066–73.
w6x Stern RC. Current concepts: the diagnosis of cystic fibrosis. N
Engl J Med 1997;336:487–91.
w7x Chillon M, Casals T, Mercier B, et al. Mutations in the cystic
fibrosis gene in patients with congenital absence of the vas
deferens. N Eng J Med 1995;332:1475–80.
w8x Collin AA, Sawyer SM, Mickle JE, Oates RD, Milunsky A,
Amos JA. Pulmonary function and clinical observations in men
with congenital bilateral absence of the vas deferens. Chest
1996;110:440–5.
w9x Stuhrmann NI, Dork T. CFTR gene mutations and male infer-
tility. Andrologia 2000;32:71–83.
w10x Lester LA, Kraut J, Lloyd-Still J, et al. Delta F508 genotype
does not predict disease severity in an ethnically diverse cystic
fibrosis population. Pediatrics 1994;93(1):114–8.
w11x Zielenski J, Corey M, Rozmahel R, et al. Detection of a cystic
fibrosis modifier locus for meconium ileus on human chro-
mosome 19q13. Nat Genet 2000;22:128–9.
w12x Rosenstein BJ, Cutting GR. Cystic fibrosis Foundation Con-
sensus Panel. The diagnosis of cystic fibrosis: a consensus
statement. J Pediatr 1998;132:589–95.
w13x Bush A, Wallis C. Time to think again — cystic fibrosis, like
cancer, is not an ‘all or none’ disease. Pediatr Pulmonol
2000;30:139–44.
w14x Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic
fibrosis gene in patients with chronic pancreatitis. N Engl J
Med 1998;339:645–52.
w15x Weiner Miller P, Hamosh A, Macek M, et al. Cystic fibrosis
transmembrane conductance regulator (CFTR) gene mutations
in allergic bronchopulmonary aspergillosis. Am J Hum Genet
1996;59:45–51.
w16x Pignatti PF, Bombieri C, Marigo C, Benetazzo MG, Luisetti M.
Increased incidence of cystic fibrosis gene mutations in adults
with disseminated bronchiectasis. Hum Mol Genet
1995;4:635–9.
w17x Cystic fibrosis mutation database. Hospital for Sick Children,
Toronto, www.genet.sickkids.on.ca
